Phaseline

Companies › iECURE

iECURE: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ECUR-506
Gene editing therapy delivering OTC gene
OTCPhase 3Ornithine Transcarbamylase DeficiencyDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06255782ECUR-506Phase 3Ornithine Transcarbamylase DeficiencyMetabolic and endocrineDec 2027

Targets

OTC (1)

Companies with the same targets

CAMP4 Therapeutics Ultragenyx Pharmaceutical Arcturus Therapeutics

Companies built like this

Spur Therapeutics Yong Zhao, MD, PhD Grace Science Orchard Therapeutics BioLab Holdings

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.